BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30387871)

  • 21. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
    Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
    Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
    Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
    Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.
    Kleckner IR; Jusko TA; Culakova E; Chung K; Kleckner AS; Asare M; Inglis JE; Loh KP; Peppone LJ; Miller J; Melnik M; Kasbari S; Ossip D; Mustian KM
    Breast Cancer Res Treat; 2021 Sep; 189(2):521-532. PubMed ID: 34191201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-Induced Peripheral Neuropathy in Egyptian Patients: Single Institution Retrospective Analysis.
    Gaballah A; Shafik A; Elhusseiny K; Ashraf M
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2223-2227. PubMed ID: 30139229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
    Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
    Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term peripheral neuropathy symptoms in breast cancer survivors.
    Mustafa Ali M; Moeller M; Rybicki L; Moore HCF
    Breast Cancer Res Treat; 2017 Nov; 166(2):519-526. PubMed ID: 28791499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials.
    Kishimoto S; Oshima N; Rinker M; Krishna MC; Takebe N
    Eur J Cancer; 2019 Jul; 115():111-119. PubMed ID: 31132741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.
    Zhi WI; Dreyfus N; Lessing A; Galantino M; Piulson L; Kot KL; Li S; Bao T
    Oncologist; 2023 Jul; 28(7):604-608. PubMed ID: 36972359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pronociceptive Roles of Schwann Cell-Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy.
    Koyanagi M; Imai S; Matsumoto M; Iguma Y; Kawaguchi-Sakita N; Kotake T; Iwamitsu Y; Ntogwa M; Hiraiwa R; Nagayasu K; Saigo M; Ogihara T; Yonezawa A; Omura T; Nakagawa S; Nakagawa T; Matsubara K
    Cancer Res; 2021 Apr; 81(8):2207-2219. PubMed ID: 33608316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
    Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
    Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study.
    Pereira S; Fontes F; Sonin T; Dias T; Fragoso M; Castro-Lopes JM; Lunet N
    Support Care Cancer; 2016 Apr; 24(4):1571-81. PubMed ID: 26384827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.
    Reyes-Gibby CC; Morrow PK; Buzdar A; Shete S
    J Pain; 2009 Nov; 10(11):1146-50. PubMed ID: 19595634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
    Tsurutani J; Sakata Y; Matsuoka T
    Breast Cancer; 2019 Mar; 26(2):235-243. PubMed ID: 30324551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.
    Lee KM; Jung D; Hwang H; Son KL; Kim TY; Im SA; Lee KH; Hahm BJ
    J Psychosom Res; 2018 May; 108():14-19. PubMed ID: 29602320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.